Acute Coronary Syndrome

News Acute Coronary Syndrome

• Novel lipid altering therapies will steer acute coronary syndrome market beyond $12 billion by 2022

  The acute coronary syndrome (ACS) market is set to rise from $7.8 billion in 2015 to $12.1 billion by 2022, at a relatively strong compound annual growth rate of 4.6%. The launch of several new lipid targeting therapies which offer clinical effectiveness for statin intolerant patients and patients w more

• FDA advisory committee recommends approval of Sanofi treatment for adults with type 2 diabetes

  Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the New Drug Application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 re more

• Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome

  New data from a clinical trial led by cardiologists at Brigham and Women's Hospital (BWH) and the Duke Clinical Research Institute indicates that the non-statin, cholesterol-lowering drug ezetimibe, when added to a statin in patients admitted to the hospital with an acute coronary syndrome, demonstr more